Skip to content

    Ajanta Pharma Limited

    Speciality pharma maker of branded generics in India, Asia & Africa, plus US generics and institution sales.

    Healthcare
    Healthcare
    View AJANTPHARM earnings calls
    ₹3,065.2
    +3.26% from avg

    Overview

    Price

    ₹3,065.2

    Market Cap

    ₹42.3k Cr

    Sector

    Healthcare

    Healthcare

    Rank

    4

    Performance

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly

    Balance Sheet

    Balance Sheet

    ₹ Cr · Annual
    Line itemFY20FY21FY22FY23FY24FY25FY26FY26
    LiabilitiesEquity Capital1817172525252525
    Reserves2.6k3.0k3.2k3.4k3.5k3.8k4.3k4.5k
    Borrowings753125363547246260
    Other Liabilities6197027111.2k9271.1k1.1k1.3k
    Total Liabilities3.3k3.7k4.0k4.6k4.5k4.9k5.7k6.0k
    AssetsFixed Assets1.5k1.5k1.5k1.5k1.5k1.8k1.9k1.9k
    CWIP132108153209256176146258
    Investments79176147535349464874588
    Other Assets1.6k1.9k2.2k2.3k2.4k2.5k2.8k3.3k
    Total Assets3.3k3.7k4.0k4.6k4.5k4.9k5.7k6.0k

    Valuation

    Assumptions

    Current — AJANTPHARM
    Price
    ₹3,065
    EPS (TTM)
    ₹84.53
    PE (TTM)
    36.3
    Profit growth
    21.5%

    The Earnings Per Share over the last 12 months.

    %

    Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).

    Pre-filled with the lower of median (34.6×) and current (36.3×) PE — the conservative anchor.

    %

    The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.

    Valuation

    Current price
    ₹3,065
    vs
    Fair value · 15% return
    ₹3,551
    16%Undervalued

    At 21.5% growth and a 35× exit, ₹3065 only delivers your return if you pay ₹3,551. The price is currently baking in 18% growth.

    EPS grows 21.5%/yr for 5 years, then fades to 6% over 2, exits at 35×.

    YearGrowthEPS (₹)
    FY2721.5%102.70
    FY2821.5%124.79
    FY2921.5%151.61
    FY3021.5%184.21
    FY3121.5%223.82
    FY3213.8% ·fade254.59
    FY336.0% ·fade269.87

    Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.

    Learn to analyse Ajanta Pharma Limited

    Guides on how to read this kind of business and the numbers that matter.